Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus
Journal of Clinical Medicine · 30.10.2024 · 13 (21) · 6509
DOI: 10.3390/jcm13216509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.10.2024. Verfasst von Juan J Gorgojo-Martínez und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, Alcorcón, 28922 Madrid, Spain. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
SGLT-2 inhibitors (SGLT-2is) are considered to be a first-line treatment for common conditions like type 2 diabetes, chronic kidney disease, and heart failure due to their proven ability to reduce cardiovascular and renal morbidity and mortality. Despite these benefits, SGLT-2is are associated with certain adverse effects (AEs), particularly genitourinary (GU) events, which can lead to treatment discontinuation in some patients. Preventing these AEs is essential for maintaining the cardiorenal benefits of SGLT-2is.
Methods
A multidisciplinary panel of experts from various medical specialties reviewed the best available evidence on GU AEs associated with SGLT-2i therapy. The panel focused on the prevention and management of genital mycotic infections, urinary tract infections, and lower urinary tract symptoms in both the general population and high-risk groups, such as renal and cardiac transplant recipients.
Results
The panel found that permanent discontinuation of SGLT-2is results in a rapid loss of cardiorenal benefits. Preventive strategies, including identifying high-risk patients before initiating therapy, are critical for minimizing GU AEs. Clinical trials show that most GU infections linked to SGLT-2i therapy are mild to moderate in severity and typically respond to standard antimicrobial treatment, without the need for discontinuation.
Conclusions
Routine discontinuation of SGLT-2is due to GU AEs is not recommended. Therapy should be resumed as soon as possible, unless severe or persistent conditions contraindicate their use, in order to preserve the significant benefits of SGLT-2is in reducing cardiovascular and renal events
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Hospital Universitario Fundación Alcorcón, Alcorcón, 28922 Madrid, Spain.
- Department of Nephrology, Valencia Clinic University Hospital, Instituto de Investigación Sanitaria (INCLIVA), Universitat de València, 46010 Valencia, Spain.
- Health Centre Casco Antiguo Cartagena, Primary Care Research Group, Biomedical Research Institute of Murcia (IMIB), 30201 Cartagena, Murcia, Spain.
- Department of Cardiology, University Hospital La Paz, IdiPAZ, Biomedical Research Center-Cardiovascular Diseases (CIBERCV-ISCIII), 28046 Madrid, Spain.
- Department of Infectious Diseases, Research Department, Hospital Universitario Fundación Alcorcón, 28922 Madrid, Spain.
ORCID-Profile: Juan J Gorgojo-Martínez, José L Górriz, Ana Cebrián-Cuenca, María Velasco Arribas
Zitieren
APA
Gorgojo-Martínez, J. J., Górriz, J. L., Cebrián-Cuenca, A., Castro Conde, A., & Velasco Arribas, M. (2024). Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine, 13(21), 6509. https://doi.org/10.3390/jcm13216509
Vancouver
Gorgojo-Martínez JJ, Górriz JL, Cebrián-Cuenca A, Castro Conde A, Velasco Arribas M. Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine. 2024;13(21):6509. doi:10.3390/jcm13216509
BibTeX
@article{GorgojoMartnez2024,
author = {Gorgojo-Martínez, Juan J and Górriz, José L and Cebrián-Cuenca, Ana and Castro Conde, Almudena and Velasco Arribas, María},
title = {Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {21},
pages = {6509},
doi = {10.3390/jcm13216509}
}
EUVIMED